drugset / Trial / NCT02212795

Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin

NCT02212795

Phase 1 Completed 18 enrolled Dong Wha Pharmaceutical Co. Ltd.
RandomizedCrossoverOpen-labelHealth-services research

Summary

Phase I clinical study to compare the pharmacokinetic profiles and bactericidal activity of Zabofloxacin 183mg, 367mg and Levofloxacin 250mg after oral administration in healthy volunteer

Timeline

Start
2014-05
Primary completion
2014-08
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Levofloxacin Small molecule 250 mg Oral
Subject Zabofloxacin Small molecule 183 mg Oral
Subject Zabofloxacin Small molecule 367 mg Oral

Indications

No indication recorded.